Crescita Retained Earnings from 2010 to 2026

CTX Stock  CAD 0.47  0.02  4.08%   
Crescita Therapeutics Retained Earnings yearly trend continues to be very stable with very little volatility. Retained Earnings are likely to drop to about -42.9 M. Retained Earnings is the cumulative amount of net income that Crescita Therapeutics retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. View All Fundamentals
 
Retained Earnings  
First Reported
2016-03-31
Previous Quarter
-45.5 M
Current Value
-44.7 M
Quarterly Volatility
5.5 M
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Crescita Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Crescita Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.2 M, Interest Expense of 55.6 K or Selling General Administrative of 10.5 M, as well as many indicators such as Price To Sales Ratio of 0.62, Dividend Yield of 0.0 or PTB Ratio of 0.67. Crescita financial statements analysis is a perfect complement when working with Crescita Therapeutics Valuation or Volatility modules.
  
This module can also supplement various Crescita Therapeutics Technical models . Check out the analysis of Crescita Therapeutics Correlation against competitors.
Evaluating Crescita Therapeutics's Retained Earnings across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Crescita Therapeutics's fundamental strength.

Latest Crescita Therapeutics' Retained Earnings Growth Pattern

Below is the plot of the Retained Earnings of Crescita Therapeutics over the last few years. It is the cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. Crescita Therapeutics' Retained Earnings historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Crescita Therapeutics' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported (45.35 M)10 Years Trend
Slightly volatile
   Retained Earnings   
       Timeline  

Crescita Retained Earnings Regression Statistics

Arithmetic Mean(37,596,700)
Coefficient Of Variation(15.21)
Mean Deviation5,317,283
Median(40,407,000)
Standard Deviation5,720,227
Sample Variance32.7T
Range14.2M
R-Value(0.84)
Mean Square Error10.4T
R-Squared0.70
Significance0.000027
Slope(949,047)
Total Sum of Squares523.5T

Crescita Retained Earnings History

2026-42.9 M
2025-40.8 M
2024-45.3 M
2023-42.6 M
2022-40.6 M
2021-41.5 M
2020-40.4 M

About Crescita Therapeutics Financial Statements

Crescita Therapeutics investors utilize fundamental indicators, such as Retained Earnings, to predict how Crescita Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Retained Earnings-40.8 M-42.9 M

Other Information on Investing in Crescita Stock

Crescita Therapeutics financial ratios help investors to determine whether Crescita Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Crescita with respect to the benefits of owning Crescita Therapeutics security.